Transdermal formulation
AssigneeEli Lilly and Company
InventorsFranklin Porter Bymaster, Harlan E. Shannon, Lisa A. Shipley, Kirti H. Valia
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for treating a condition associated with muscarinic receptor modulation using a 3-4-(butylthio)-1,2,5-thiadiazol-3-yl!-1-azabicyclo-2.2.2!octane transdermal formulation. The invention provides desired transdermal 3-4-(butylthio)-1,2,5-thiadiazol-3-yl!-1-azabicyclo2.2.2!octane patch formulations.
Claims13
A transdermal patch prepared using a formulation comprising from about 66 to 99.8% acrylate adhesive, and the compound 3-4-(butylthio)-1,2,5-thiadiazol-3-yl!-1-azabicyclo2.2.2!octane in an amount so that the patch contains between about 1 to about 100 mg of the compound.
A transdermal patch prepared using a formulation comprising the compound 3-4-(butylthio)-1,2,5-thiadiazol-3-yl!-1-azabicyclo2.2.2!octane in an amount so that the patch contains between about 1 to about 100 mg of the compound distributed in a matrix comprising a pressure-sensitive adhesive.
A method for treating a condition associated with modulation of a muscarinic receptor comprising administering 3-4-(butylthio)-1,2,5-thiadiazol-3-yl!-1-azabicyclo2.2.2!octane using a transdermal patch.
Dependencies are inferred from the claim text.